<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: Expression levels of the urokinase-type plasminogen activator receptor (uPAR) represent an established biomarker for poor prognosis in a variety of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of the present study was to explore whether noninvasive PET can be used to perform a quantitative assessment of expression levels of uPAR across different human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> in mice and to illustrate the clinical potential of uPAR PET in future settings for individualized therapy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: To accomplish our objective, a linear, high-affinity uPAR <z:chebi fb="7" ids="16670">peptide</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi>, AE105, was conjugated with DOTA and labeled with (64)Cu ((64)Cu-DOTA-AE105) </plain></SENT>
<SENT sid="3" pm="."><plain>Small-animal PET was performed in 3 human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> xenograft mice models, expressing different levels of human uPAR, and the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake was correlated with the uPAR expression level determined by uPAR enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake pattern of this tracer was furthermore compared with (18)F-FDG uptake, and finally the correlation between sensitivity toward <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> therapy and uPAR expression level was investigated </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The uPAR-targeting PET tracer was produced in high purity and with high specific radioactivity </plain></SENT>
<SENT sid="6" pm="."><plain>A significant correlation between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake of (64)Cu-DOTA-AE105 and uPAR expression was found (R(2) = 0.73; P &lt; 0.0001) across 3 cancer xenografts, thus providing a strong argument for specificity </plain></SENT>
<SENT sid="7" pm="."><plain>A significantly different uptake pattern of (64)Cu-DOTA-AE105, compared with that of (18)F-FDG, was observed, thus emphasizing the additional information that can be obtained on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biology using (64)Cu-DOTA-AE105 PET </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, a significant correlation between baseline uPAR expression and sensitivity toward <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> was revealed, thus illustrating the possible potentials of uPAR PET in a clinical setting </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Our results clearly demonstrate that the <z:chebi fb="7" ids="16670">peptide</z:chebi>-based PET tracer (64)Cu-DOTA-AE105 enables the noninvasive quantification of uPAR expression in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in vivo, thus emphasizing its potential use in a clinical setting to detect <z:e sem="disease" ids="C0677898" disease_type="Neoplastic Process" abbrv="">invasive cancer</z:e> foci and for individualized <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy </plain></SENT>
</text></document>